RUO toTraction Adeptrix offers research-use-only exoBAMS technology that enables discovery-driven biomarker profiling from extracellular vesicles, presenting a clear sell to pharma, biotech, and academic research groups seeking advanced biomarker discovery and translational study capabilities.

EV Enrichment Advantage The platform selectively isolates disease-relevant EV populations before analysis, delivering cleaner molecular readouts and improved reproducibility, a compelling differentiator when pitching high-value biomarker strategies and precision medicine programs.

Collaborative Flexibility Adeptrix emphasizes discovery-driven collaborations with flexible pilot studies and scalable workflows, aligning well with customers looking to test hypotheses, de-risk early research decisions, or accelerate pilot projects.

Mass Spectrometry Tie Integration with MALDI MS workflows and Bruker collaboration positions Adeptrix as a complementary tool for organizations with existing mass spectrometry infrastructure seeking enhanced liquid biopsy insights without overhauling their platforms.

High Growth Pitch With revenue in the low-to-mid range and a notable niche in oncology and complex diseases, there are opportunities to upsell expanded biomarker panels, AV/EV targeting strategies, and broader virology and diagnostic toolkits through strategic partnerships and funded programs.